MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Saturday, April 28, 2018

Multiple Sclerosis Video: 15 Best Ways to Improve Sexual Functioning in MS





Sex is a major contributor to our quality of life & we shouldn't give that up just because we happen to have a chronic condition such as MS.
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::


CLICK BOX to SUBSCRIBE to our MS Learning Channel on YouTube: 

                      
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Wednesday, April 25, 2018

Israeli Scientists May Have Found A Cure for MS, Alzheimer’s, Crohn’s And Colitis in One Single Drug



Click here or the above box to listen to this message



::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

                      
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Research Unveil Another Possible Epstein-Barr Virus Link to MS

April 24, 2018 - Ed Tobias


Epstein-Barr virus and MS
For years researchers have believed a link exists between the Epstein-Barr virus(EBV) and multiple sclerosis. But scientists have had a hard time finding a precise association.
Now, the National Institutes of Health (NIH) are reporting another possible connection. Researchers at the Center for Autoimmune Genomics and Etiologyat Cincinnati Children’s Hospital Medical Center have found a viral protein in EBV-infected cells. They think that the protein may turn on a “switch” that activates genes that are associated with an increased risk of autoimmune diseases. MS, of course, is an autoimmune disease.
Most people are infected with EBV. According to the Centers for Disease Control, it’s one of the most common human viruses. It usually appears in early childhood and its symptoms are generally very mild or don’t appear at all. But the EBV infection remains with people.
Scientists know that the EBV infection can produce a protein called EBNA2. In this new research, they found that EBNA2 activates some of the human genes associated with the risk of lupus and several other autoimmune diseases, including multiple sclerosis. Simply put, it flips that autoimmune disease “switch.”
“These findings suggest that EBV infection in cells can actually drive the activation of these genes and contribute to an individual’s risk of developing the disease,” said lead researcher John B. Harley, MD, PhD, in an NIH news release.

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

                       
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Is the MRI Contrasting Agent Gadolinium Safe? (Part 1)

contrast






When a doctor orders an MRI with contrast, gadolinium is usually the contrasting agent used. Gadolinium is injected into the patient’s vein after the radiologist takes the first round of MRI images. This helps the radiologist receive sharper, more readable images.
In the case of multiple sclerosis (MS), the images taken with a contrasting agent highlight inflammation. The highlighted areas can show new or active lesions on the brain and the spine.
Gadolinium offers extra insight into our body’s condition. But is it safe? That question is part of a growing debate in the MS community.
Recent findings have shown that in some cases, the body can retain gadolinium in its tissues and brain for years.     - Continue Reading
                      
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Video: What is: Occupational Therapy for MS



What is Occupational Therapy? How can an OT help someone impacted by MS? We cover the most common OT consults at our center, what is a "Home Safety Evaluation," as well as how OT can help with driving safety and independence! Jenny leaves us with a call to action!

======================================
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

                      
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

#AAN2018 – High Fish Consumption Linked to Lower MS Risk




A diet rich in fish consumption and supplemented with omega-3 polyunsaturated fatty acids (PUFAs) is linked to a reduction of 45 percent in the risk of developing multiple sclerosis, a study shows.
The results confirming previous research will be shared April 26 at the 2018 Annual Meeting of the American Academy of Neurology, in a presentation titled “Fish, Fatty Acid Biosynthesis Genes, and Multiple Sclerosis Susceptibility.”
A fish-rich diet has been associated with a lower risk of MS. Fish are the best source of omega-3 PUFAs, commonly called fish oils; but it remains unclear if PUFAs are the reason for a lower MS risk, or if it’s another type of nutrient.

Also, genetic variations in the nucleotides (building blocks) of the fatty acid desaturase (FADS) gene – leading to changes in fatty acid levels – have been linked with cognition, cardiovascular disease and inflammation. However, “whether they are associated with MS is unknown,” researchers wrote.
The team tackled these questions and examined how fish consumption affected the risk of MS in 1,153 participants of the MS Sunshine Study, a multi-ethnic study investigating the incidence of MS or its precursor, clinically isolated syndrome (CIS).
In the study, high fish intake was defined as consuming fish at least once a week, or one to three servings per month combined with fish oil supplements.
READ MORE


::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::


CLICK BOX to SUBSCRIBE to our MS Learning Channel on YouTube: 

                      
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

#AAN2018 – Celgene to Present Latest Data on Ozanimod’s Safety and Effectiveness

Celgene’s oral treatment candidate ozanimod can effectively reduce relapse rates in multiple sclerosis (MS) patients with mild to moderate disability, results of two Phase 3 trials show.
The company will present data on the SUNBEAM (NCT02294058) and RADIANCE (NCT02047734) trials in two presentations at the 2018 Annual Meeting of the American Academy of Neurology (AAN), underway in Los Angeles through April 27.
Both studies evaluated the efficacy and safety of 1 mg or 0.5 mg capsules of ozanimod compared to intramuscular injections of 30 μg of Biogen’s Avonex(interferon beta-1a) in a total of 2,659 people with relapsing MS.
During the SUNBEAM trial, patients treated daily with both ozanimod doses experienced fewer relapses per year compared to those treated with Avonex — 0.195 with ozanimod at 1 mg, 0.210 with Ozanimod at 0.5 mg, and 0.338 for those given Avonex as a weekly injection, the data show.
This beneficial effect was found both in patients new disease-modifying therapies, as well as in those who had already used such therapies.
Similar results were also reported in the RADIANCE trial, which evaluated the treatment’s effectiveness over 24 months. Both ozanimod doses were seen to be more effective in reducing annualized relapse rates (ARR) than Avonex — 0.157 and 0.228 with ozanimod 1 and 0.5 mg, respectively, and 0.246 with Avonex.
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

CLICK BOX to SUBSCRIBE to our MS Learning Channel on YouTube: 

                      
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Maneuvering of the Body, with Interactive Exercise



click the above box to watch and learn from this video




::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::


                      
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Monday, April 23, 2018

Blood Stem Cell Transplant Superior to DMDs in Highly Active RRMS, MIST Trial Shows

April 23, 2018

HSCT







 Autologous non-myeloablative hematopoietic stem cell transplant was found to be significantly better at reducing risks for disability in relapsing-remitting multiple sclerosis (RRMS) patients compared to disease-modifying drug (DMD) therapies, interim results of the MIST clinical trial show.

READ MORE


::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::


CLICK BOX to SUBSCRIBE to our MS Learning Channel on YouTube: 

                      
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

NEW OCREVUS (OCRELIZUMAB) DATA AT AAN DEMONSTRATE SIGNIFICANT REDUCTIONS IN DISEASE ACTIVITY AND DISABILITY PROGRESSION IN RELAPSING MULTIPLE SCLEROSIS

April 23, 2018

·      Four years of continuous treatment with OCREVUS showed a sustained reduction in underlying disease activity in relapsing MS (RMS) in analysis from the open-label extension period
·      Additional analyses show OCREVUS delayed cognitive decline and improved cognitive function in RMS, as measured by Symbol Digit Modalities Test
·      OCREVUS reduced the presence of nerve damage and inflammation biomarkers in people with RMS shown in interim data from a Phase III study
·      New safety data are consistent with OCREVUS’ favorable benefit-risk profile for both RMS and primary progressive MS

·      Over 40,000 patients treated with OCREVUS globally

SOUTH SAN FRANCISCO, Calif. – April 23, 2018 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new OCREVUS (ocrelizumab) data were presented at the 70th American Academy of Neurology (AAN) Annual Meeting from April 21-27 in Los Angeles, California. The data showcase the efficacy of OCREVUS in relapsing multiple sclerosis (RMS) through several measures of underlying disease activity and disability progression, including magnetic resonance imaging (MRI), cognitive function, and spinal fluid biomarkers of inflammation and neurodegeneration. New safety data remain consistent with OCREVUS’ favorable benefit-risk profile in both relapsing and primary progressive multiple sclerosis (PPMS).

“The OCREVUS data shared at AAN show the impact of this targeted B cell therapy on slowing disability progression in MS, and further support the approach of early treatment. In the extension studies, patients who received OCREVUS continuously experienced less disease progression than those who began treatment at a later time point,” said Stephen Hauser, M.D., chair of the Scientific Steering Committee of the OPERA studies, director of the Weill Institute for Neurosciences and chair of the Department of Neurology at the University of California, San Francisco. “It is encouraging that with up to four years of data, we continue to see a robust effect and a consistent safety profile.”


After four years of continuous treatment, the benefits of OCREVUS in reducing underlying disease activity in RMS were sustained, as shown in a platform presentation measuring brain MRI activity through the randomized and open-label extension (OLE) periods of the Phase III studies. Patients who stayed on OCREVUS maintained low numbers of T1 gadolinium-enhancing (T1Gd+) lesions (0.017 pre-OLE to 0.17 T1Gd+ lesions per scan at year four [year two of the OLE phase]) and new/enlarging T2 (N/ET2) lesions [0.052 pre-OLE to 0.080 N/ET2 lesions per scan] through year two of the OLE phase. Patients who switched from Rebif® (interferon beta-1a) to OCREVUS at the start of the OLE period had a near-complete silencing of T1Gd+ lesions per scan at one and two years (0.476 pre-OLE to 0.007 and 0.004 T1Gd+ lesions per scan), as well as an 85 and 97 percent decrease in N/ET2 lesions per scan at years one and two, respectively (2.159 pre-OLE to 0.333 and 0.063 N/ET2 lesions per scan).





::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::


CLICK BOX to SUBSCRIBE to our MS Learning Channel 
on YouTube: 

                      
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Sunday, April 22, 2018

B-a-a-a --- Exposure to sheep could trigger multiple sclerosis, study suggests


Sheep can carry a toxin which may trigger MS, scientists believe 


Exposure to a toxin primarily found in sheep could be linked to the development of multiple sclerosis, a new studysuggests.
More than 100,000 people in Britain have been diagnosed with MS, which occurs when the immune system attacks the protective coating surrounding nerve cells in the brain and spinal cord.
The condition leads to inflammation, pain, disability and in severe cases, early death, but experts still do not know the underlying cause.
Now researchers at the University of Exeter have discovered that nearly half of the MS sufferers that they studied had been infected at some time in their lives by epsilon toxin.
The toxin is produced in the gut of sheep by the Clostridium Perfringens bacterium and can also be found in the soil.  
Researchers looked at 250 people - half of whom had MS -  and found 43 per cent of MS patients were carrying antibodies to epsilon toxin, proving it had been in the body long enough for the immune system to produce a response.






                      
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Boster's Views and MS News: New developments in volumetric imaging

The authors conclude, "New developments in volumetric imaging have the potential to improve sensitivity as well as specificity in detecting and hence monitoring disease-related CNS volume changes in MS"

Abstract

PURPOSE OF REVIEW:

Volumetric analysis of brain imaging has emerged as a standard approach used in clinical research, e.g., in the field of multiple sclerosis (MS), but its application in individual disease course monitoring is still hampered by biological and technical limitations. This review summarizes novel developments in volumetric imaging on the road towards clinical application to eventually monitor treatment response in patients with MS.


::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides Multiple Sclerosis education, information, 
resources and services that will benefit many affected by MS. 


SUBSCRIBE to our MS Learning Channel on YouTube: 

                      
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Multiple Sclerosis - Important Questions and the answers

Information showing below is found on National MS Society website

Click each to learn more

  • What is multiple sclerosis?
  • Who gets MS?
  • How many people have MS?
  • What are the different types of MS?
  • What are the typical symptoms of MS?
  • What causes the symptoms?
  • Does MS always cause paralysis?
  • Is MS fatal?
  • Is MS contagious or inherited?
  • Can MS be cured?
  • What can be done about MS now?
  • Why is early treatment important?
  • Why is MS so difficult to diagnose?




SUBSCRIBE to our MS Learning Channel on YouTube: 

                      
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::